Waters Corporation Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Life Sciences Tools and Services | Market Cap: ₹36.0K Cr
- The company expects total reported 2026 revenue of approximately $6.405 billion to $6.455 billion, including $35 million of revenue synergies from acquired businesses. - Full-year 2026 adjusted EBIT margin expected at 28.2%, reflecting strong first quarter results and cost synergy actions starting in Q3.
From Waters Corporation's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹366.67
Market Cap
₹36.0K Cr
P/E Ratio
43.1
Revenue Rank
Margin Rank
How does Waters Corporation rank in Life Sciences Tools and Services?
Compare Waters Corporation against every Life Sciences Tools and Services company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 3- →The company expects total reported 2026 revenue of approximately $6.405 billion to $6.455 billion, including $35 million of revenue synergies from acquired businesses.
- →Organic constant currency revenue growth guidance for full year 2026 is raised to 6.5% to 8%, reflecting strong Q1 performance and $15 million expected revenue synergy contribution.
- →Second quarter 2026 organic constant currency revenue growth is expected at 6% to 8%, with reported revenues guided at $814 million to $829 million.
- →Second half of 2026 organic growth is prudently modeled at ~6%, derisking outlook due to macro factors and fewer working days.
- →Acquired Biosciences and Diagnostic Solutions businesses are expected to generate roughly $3.035 billion revenue in 2026 with ongoing commercial and operational initiatives driving growth.
- →Pricing discipline, localization efforts (especially in China), and new product launches (e.g., BACTEC FXI) are key growth drivers.
- →Long term aims include mid-to-high single-digit organic growth, increasing synergies, and margin expansion.
📈 Profitability & Margins
Rank 2- →Full-year 2026 adjusted EBIT margin expected at 28.2%, reflecting strong first quarter results and cost synergy actions starting in Q3.
- →Adjusted earnings per fully diluted share (EPS) guidance raised to $14.40–$14.60 for 2026, up $0.10 from prior, reflecting strong Q1 performance and updated FX rates.
- →Second quarter adjusted EPS expected in range $2.95 to $3.05, flat to 3.4% growth, despite higher interest costs and shares issued; cost synergies to start benefiting P&L from Q3.
- →Mid-teens adjusted EPS growth algorithm targeted over the next several years, driven by operational improvements, innovation, and synergy realization.
- →Organic constant currency revenue growth guidance raised to 6.5% to 8% for 2026, with continued momentum and $15 million revenue synergies embedded.
- →Executives expect at least 100 basis points adjusted operating margin expansion annually through decade-end.
🏗️ Capital Expenditure Plans
Yes- →Localization of manufacturing in China for Flow cytometry instruments to improve market access and reduce export complexity, starting in Q3 2026 (Page 3).
- →Investment in new product launches such as next-generation Microflow LC Chemistry Columns with MaxPeak Premier technology and omniDAWN Multi Angle Light Scattering Detector (Page 3).
- →Launch of next-generation BACTEC FXI blood culture system with CE marking, with ongoing regulatory approvals in key markets (Page 3).
- →Continuous investments in R&D, with 70%-80% dedicated to bioseparations (Page 11).
- →Operational improvements under the 180-day plan including increased commercial activity, pricing initiatives, and funnel reviews (Page 3).
- →Cost synergies and broader cost actions expected to enhance margins but no specific capital expenditure figures given (Page 5).
💰 Fundraising & Capital Structure
No information- →There is no explicit mention of new fundraising through debt or equity in the provided pages.
- →Net interest expense for the year is expected to be approximately $186 million, indicating existing debt servicing but no new debt issuance announced.
- →The company discusses operational improvements, synergy realization, and cost management rather than capital raising.
- →No reference to new equity issuance or planned fundraising activities.
- →Free cash flow was $42 million in Q1, affected by deal-related costs, implying reliance on existing funds.
- →Overall focus is on growth, revenue synergies, and margin expansion without highlighted capital raise plans.
📋 Order Book & Pipeline
Yes- →The company reports very strong orderbook and funnel visibility, described as "better than they ever have" (Page 9).
- →Forecast accuracy has improved due to enhanced collaboration and integration efforts post-acquisition (Page 9).
- →The 180-day growth revitalization plan has increased commercial activity, leading to stronger funnel trends and overall momentum (Page 3).
- →Pricing initiatives and deal desks are being implemented, enhancing revenue potential but not yet fully reflected in guidance (Page 12).
- →Continued strong demand in key segments like LCMS instruments, chemistry, and service, with sustained instrument replacement cycles giving a good runway into 2027 (Page 13).
- →Despite macro uncertainties, the company expresses high confidence in the strength of the funnel and orderbook for the remainder of the year (Pages 10 and 13).
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Life Sciences Tools and Services this season
- Revvity, Inc. (Q2 FY26)
Revvity, Inc. Q2 FY26 quarterly results analysis. 2026 revenue guidance updated to $2.81 billion - $2.84 billion, with pro forma organic growth expected at 3% t
- Medpace Holdings, Inc. (Q2 FY26)
Medpace Holdings, Inc. Q2 FY26 quarterly results analysis. Revenue is expected to remain within the current guidance range for 2026 despite higher cancellations
- Illumina, Inc. (Q2 FY26)
Illumina, Inc. Q2 FY26 quarterly results analysis. Illumina expects continued strong momentum in clinical sales, projecting mid-teens growth for the clinical ma
- Mettler-Toledo International Inc. (Q2 FY26)
Mettler-Toledo International Inc. Q2 FY26 quarterly results analysis. The company expects local currency sales growth of approximately 4% for full year 2026, in
Frequently Asked Questions
What were Waters Corporation Q2 FY26 results?
- The company expects total reported 2026 revenue of approximately $6.405 billion to $6.455 billion, including $35 million of revenue synergies from acquired businesses. - Full-year 2026 adjusted EBIT margin expected at 28.2%, reflecting strong first quarter results and cost synergy actions starting in Q3.
What is Waters Corporation share price analysis?
Waters Corporation currently shows a below-average growth signal. The stock trades at a P/E of 43.1 with a market cap of $36,002. Investors should review the full earnings analysis for detailed insights.
Is Waters Corporation planning capital expenditure?
- Localization of manufacturing in China for Flow cytometry instruments to improve market access and reduce export complexity, starting in Q3 2026 (Page 3).
Keep Waters Corporation on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.